Azenta (Azenta) Gross-Profit-to-Asset % : 8.62% (As of Dec. 2023)

View and export this data going back to 1995. Start your Free Trial

What is Azenta Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Azenta's annualized Gross Profit for the quarter that ended in Dec. 2023 was $246.0 Mil. Azenta's average Total Assets over the quarter that ended in Dec. 2023 was $2,855.0 Mil. Therefore, Azenta's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was 8.62%.

Azenta Gross-Profit-to-Asset % Historical Data

The historical data trend for Azenta's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Azenta Gross-Profit-to-Asset % Chart

Azenta Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

10.31

11.20

14.43

9.23

7.97

Azenta Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Gross-Profit-to-Asset %	Get a 7-Day Free Trial															8.43	6.51	8.61	9.14	8.62

Competitive Comparison of Azenta's Gross-Profit-to-Asset %

For the Medical Instruments & Supplies subindustry, Azenta's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Azenta's Gross-Profit-to-Asset % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Azenta's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Azenta's Gross-Profit-to-Asset % falls into.

Azenta Gross-Profit-to-Asset % Calculation

Azenta's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Sep. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Sep. 2023 )	/	( (Total Assets (A: Sep. 2022 )	+	Total Assets (A: Sep. 2023 ))	/ count )
	=	263.14	/	( (3716.122	+	2885.72)	/ 2 )
	=	263.14	/	3300.921
	=	7.97 %

Azenta's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Dec. 2023 )	/	( (Total Assets (Q: Sep. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	246.048	/	( (2885.72	+	2824.314)	/ 2 )
	=	246.048	/	2855.017
	=	8.62 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Dec. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Azenta Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Azenta's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Azenta (Azenta) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Azenta Inc (NAS:AZTA) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

BA3:Germany

Address

200 Summit Drive, 6th Floor, Burlington, MA, USA, 01803

Website

https://www.azenta.com

Azenta Inc is a provider of life sciences solutions, enabling impactful breakthroughs and therapies to market faster. It provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. The company has two reportable segments that are Life Sciences Products and Life Sciences Services. It generates a substantial part of its revenue from its Life Sciences Services segment.

Executives

Herman Cueto	officer: EVP, Chief Financial Officer	C/O AZENTA, INC., 200 SUMMIT DRIVE, 6TH FLOOR, BURLINGTON MA 01803
Violetta Hughes	officer: VP, Chief Accounting Officer	C/O AZENTA, INC., 200 SUMMIT DRIVE, 6TH FLOOR, BURLINGTON MA 01803
David C Gray	officer: Chief Strategy & New Business	C/O GT SOLAR INTERNATIONAL, INC., 243 DANIEL WEBSTER HIGHWAY, MERRIMACK NH 03054
Joseph R Martin	director
Dorothy E Puhy	director	DANA FARBER CANCER INSTITUTE, 44 BINNEY STREET, RM. D1632, BOSTON MA 02115
Tina Susan Nova	director	C/O ARENA PHARMACEUTICALS, INC., 6166 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Mitchell Coyne	officer: SVP and GM, Life Sciences Proj	15 ELIZABETH DRIVE, CHELMSFORD MA 01824
Ginger Zhou	officer: SVP and General Manager, Genom	15 ELIZABETH DRIVE, CHELMSFORD MA 01824
Matthew Mcmanus	officer: EVP & Chief Operating Officer	15 ELIZABETH DRIVE, CHELMSFORD MA 01824
Lindon G Robertson	officer: EVP & Chief Financial Officer	C/O GRAFTECH INTERNATIONAL LTD., 12900 SNOW ROAD, PARMA OH 44130
Kimberly Crowley	officer: Chief Human Resources Officer	15 ELIZABETH DRIVE, CHELMSFORD MA 01824
Vandana Sriram	officer: VP, Finance & Corp. Controller	15 ELIZABETH DRIVE, CHELMSFORD MA 01824
Jesus Linda De	officer: Chief Commercial Officer, LS	15 ELIZABETH DRIVE, CHEMSFORD MA 01824
David Jarzynka	officer: Sr. VP, General Manager	15 ELIZABETH DRIVE, CHELMSFORD MA 01824
Robin Vacha	officer: SVP, GM BLS-Products	15 ELIZABETH DRIVE, 15 ELIZABETH DRIVE, CHELMSFORD MA 01824